Niloufar Marsousi, Serge Rudaz, Jules A. Desmeules and Youssef Daali* Pages 1 - 7 ( 7 )
BACKGROUND: Ticagrelor is a highly recommended new antiplatelet agent for treatment of patients with acute coronary syndrome at moderate or high ischemic risk. There is a real need of rapid and accurate analytical methods for ticagrelor determination in biological fluids for pharmacokinetic studies. In this study, a sensitive and specific LC-MS method was developed and validated for quantification of ticagrelor and its active metabolite (AM) in human plasma over expected clinical concentrations.
METHODS: Samples were handled by liquid-liquid extraction (LLE). A linear gradient was applied with a mobile phase composed of formic acid 0.1% and acetonitrile with 0.1% of formic acid using a C18 reversed-phase column. MS spectra were obtained by electrospray ionization in negative mode and optimized at 521.4→360.9 m/z, 477.2→361.2 m/z and 528.1→367.9 m/z transitions for ticagrelor, AM and ticagrelor-d7, respectively.
RESULTS: This method allowed rapid elution, in less than 4 minutes, and quantification of concentrations as low as 2 ng/mL for ticagrelor and 1 ng/mL for AM using only 100 µL of human plasma. LLE using hexane/ethyl acetate (50/50) was an optimal compromise in terms of extraction recovery and endogenous compounds interference. Trueness values of 87.8% and 89.5% and precisions of 84.1% and 93.8% were obtained for ticagrelor and AM respectively. Finally, usefulness of the method was assessed in a clinical trial where a single 180 mg ticagrelor was orally administered to healthy male volunteers. Pharmacokinetic parameters of ticagrelor and its active metabolite were successfully determined.
CONCLUSION: A sensitive and specific quantification LC-MS-MS method was developed and validated for ticagrelor and its active metabolite determination in human plasma. The method was successfully applied to a clinical trial where a single ticagrelor 180 mg dose was orally administered to healthy male volunteers. The described method allows quantification of concentrations as low as 2 ng/mL of ticagrelor and 1 ng/mL of the metabolite using only 100 µL of plasma.
Ticagrelor, LC-MS/MS, Quantification, Validation, Biological matrix
Clinical Pharmacology and Toxicology Service, Geneva University Hospitals, School of pharmaceutical sciences, Geneva University, Clinical Pharmacology and Toxicology Service, Geneva University Hospitals, Clinical Pharmacology and Toxicology Service, Geneva University Hospitals